ASD/PFO devices: what is in the pipeline?
ASD/PFO devices: what is in the pipeline?
复制标题
DOI：
10.1111/j.1540-8183.2007.00303.x
复制
发表时间：
2007-12-01
影响因子：
2.1
通讯作者：
Sievert, Horst
中科院分区：
文献类型：
--
作者：
Majunke, Nicolas;Sievert, Horst
自从20世纪70年代中期King和米尔斯首次描述了房间隔缺损（ASD）封堵器以来，已经开发了许多器械。迄今为止，用于闭合先天性心脏缺陷的各种经导管装置和方法目前可商购获得或在临床试验中获得。这些器械专门设计用于ASD和卵圆孔未闭（PFO）。心内分流的介入治疗的趋势是使用缺陷特异性系统和新器械，以最大限度地减少留在心房内的异物。本综述首先关注美国未批准但其他地方批准的新器械，然后回顾PFO和ASD闭合的实验器械。
Since the initial description of an atrial septal defect (ASD) occluding device in the mid-1970s by King and Mills, a number of devices have been developed. To date, various transcatheter devices and methods to close congenital heart defects are currently available commercially or within clinical trials. Devices have been designed specifically for the ASD and patent foramen ovale (PFO). The trend in interventional treatment of intracardiac shunts is toward defect-specific systems and new devices minimizing the foreign material left in the atria. This review first focuses on new devices that are not approved in the United States but are elsewhere, and then reviews the experimental devices for PFO and ASD closure.